IceCure CEO Issues Letter to Shareholders: Reports Record Fourth Quarter and Full Year 2025 ProSense® Sales [Yahoo! Finance]
IceCure Medical Ltd. - Ordinary Shares (ICCM)
Company Research
Source: Yahoo! Finance
for the local treatment of low-risk breast cancer, addressing a market opportunity of approximately 200,000 patients Record European sales, driven by positive effects of U.S. clearance and continued growing adoption of ProSense® cryoablation for breast cancer in key markets Record number of peer-reviewed publications and presentations at global conferences demonstrates growing clinical evidence for cryoablation of breast, musculoskeletal, and kidney cancers with ProSense® CAESAREA, Israel Jan. 12, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today issued the following letter to shareholders from its Chief Executive Officer, Eyal Shamir. Dear shareholders, 2025 was a pivotal year for IceCure – we were granted the U.S. Food and Drug Administration's ("FDA") marketing authorization for ProSe
Show less
Read more
Impact Snapshot
Event Time:
ICCM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ICCM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ICCM alerts
High impacting IceCure Medical Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
ICCM
News
- IceCure CEO Issues Letter to Shareholders: Reports Record Fourth Quarter and Full Year 2025 ProSense® SalesPR Newswire
- IceCure Expected to Report Record Fourth Quarter Sales in North America Driven by Recent FDA Clearance of ProSense® Cryoablation for Low-Risk Breast CancerPR Newswire
- IceCure's ProSense® Cryoablation Featured in 4 Independent Breast Cancer Studies Presented at Radiological Society of America 2025 Annual Meeting [Yahoo! Finance]Yahoo! Finance
- IceCure's ProSense® Cryoablation Featured in 4 Independent Breast Cancer Studies Presented at Radiological Society of America 2025 Annual MeetingPR Newswire
- IceCure Receives Notice of Patent Allowance in China for a Novel Cryogen Flow Control to Optimize Patient Cryoablation Outcomes [Yahoo! Finance]Yahoo! Finance
ICCM
Earnings
- 8/13/25 - Miss
ICCM
Sec Filings
- 1/12/26 - Form 6-K
- 1/9/26 - Form 6-K
- 1/8/26 - Form 6-K
- ICCM's page on the SEC website